Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.97

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given an average recommendation of “Buy” by the nine analysts that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.97.

Several brokerages have recently issued reports on VYGR. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a report on Wednesday, March 12th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, March 13th. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock.

Voyager Therapeutics Stock Down 7.4 %

Voyager Therapeutics stock opened at $3.38 on Thursday. The stock has a market cap of $186.60 million, a PE ratio of 4.76 and a beta of 0.99. Voyager Therapeutics has a 12-month low of $3.36 and a 12-month high of $10.66. The business’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $5.62.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the firm posted $1.25 earnings per share. As a group, analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in Voyager Therapeutics by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after acquiring an additional 6,740 shares during the last quarter. FMR LLC boosted its position in shares of Voyager Therapeutics by 26.9% during the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Barclays PLC grew its stake in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Voyager Therapeutics by 23.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock worth $223,000 after purchasing an additional 7,573 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock valued at $405,000 after buying an additional 2,354 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.